UPDATE 1-Amgen, Novartis aim for big, crowded migraine market after new drug data

UPDATE 1-Amgen, Novartis aim for big, crowded migraine market after new drug data


An Amgen sign is seen at the company's office in South San Francisco, California in this October 21, 2013 file photo. Amgen Inc and Novartis said late on Wednesday that episodic migraine sufferers reported fewer debilitating headaches per month after using the companies' investigational drug erenumab, compared to trial participants who got a placebo.



from Biotech News